共45只个股出现了机构的身影。 当天机构净卖出前三的股票分别是金风科技、芯源微、强一股份，净流出金额分别是6.69亿元、6.33亿 元、3.15亿元。 | 17 序 | 1.08 | 机构资金参与个股一览 | | --- | --- | --- | | 证券间称 | 目涨跌幅 | 机构净买入(万元) | | 航天电器 | 10.01% | 27618.62 | | 臻镭科技 | 15.21% | 25901.31 | | 鹭燕医药 | 10.00% | 18660.13 | | 海兰信 | 20.00% | 13543.14 | | 乾脂光电 | 20.01% | 12617.20 | | 砂电股份 | 14.86% | 12367.07 | | 恒坤新材 | 3.13% | 12153.16 | | 紫燕食品 | 7.88% | 7454.63 | | 爰朋医疗 | 19.99% | 6608.88 | | 纳百川 | 5.08% | 6453.83 | | 航天南湖 | 20.00% | 6139.24 | | 顺灏股份 | 10.02% | 5011.72 | | 邵阳液压 | 20.01% | 444 ...

Market Overview - The pharmaceutical commercial sector increased by 0.79% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Top Gainers in Pharmaceutical Sector - Luyuan Pharmaceutical (002788) closed at 27.49, up 10.00% with a trading volume of 812,100 shares and a transaction value of 2.156 billion [1] - Saili Medical (603716) closed at 26.66, up 9.98% with a trading volume of 700,200 shares and a transaction value of 1.802 billion [1] - Dajia Weikang (301126) closed at 13.50, up 5.47% with a trading volume of 184,200 shares and a transaction value of 245 million [1] Other Notable Stocks - Run Da Medical (603108) closed at 16.31, up 5.23% with a trading volume of 378,400 shares and a transaction value of 614 million [1] - Huaren Health (301408) closed at 20.16, up 3.38% with a trading volume of 503,400 shares and a transaction value of 1.016 billion [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 94.4079 million from institutional investors, while retail investors saw a net inflow of 213 million [2] - The overall market showed a mixed trend with some stocks experiencing significant outflows from institutional and speculative funds [2] Individual Stock Fund Flow - Saili Medical (603716) had a net inflow of 304 million from institutional investors, but a net outflow of 108 million from speculative funds [3] - Run Da Medical (603108) saw a net inflow of 62.5499 million from institutional investors, while experiencing outflows from both speculative and retail investors [3] - Huaren Health (301408) had a net inflow of 41.8956 million from institutional investors, but a significant outflow of 64.016 million from retail investors [3]

每经AI快讯，1月8日，鹭燕医药（002788）公告称，公司股票交易价格连续两个交易日内收盘价格涨 幅偏离值累计超过20%，属于股票交易异常波动的情况。经核实，公司前期披露的信息不存在需要更 正、补充之处，近期公司经营情况正常，内外部经营环境未发生重大变化，公司、控股股东和实际控制 人不存在关于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项。股票异常波动期间， 控股股东、实际控制人不存在买卖公司股票的情形。 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2026-001 鹭燕医药股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 鹭燕医药股份有限公司（以下简称"公司"）股票交易价格连续两个交易日内（2026 年 1 月 7 日、2026 年 1 月 8 日）收盘价格涨幅偏离值累计超过 20%，根据深圳证券交易所的有 关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票交易异常波动情况，根据相关规定的要求，公司对有关事项进行了核查， 现就相关情况说明如下： 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 3、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的 未公开重大信息； 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项，或 处于筹划阶段的重大事项； 5、股票异常波动期间，控股股东、实际控制人不存在买卖公司股票的情形。 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券 ...

Group 1 - Lu Yan Pharmaceutical has achieved 8 consecutive limit-up trading days within 15 days, indicating strong market interest [1] - The stock reached a trading limit at 11:11 AM today with a transaction volume of 1.694 billion yuan and a turnover rate of 16.86% [1] - The recent fluctuations in the brain-computer interface sector have attracted market attention, with financing dynamics in related fields contributing to this interest [1] Group 2 - Lu Yan Pharmaceutical has acknowledged the importance of artificial intelligence and big data in the medical and pharmaceutical fields, indicating ongoing research and exploration in these areas [1] - The recent performance of the stock may be influenced by these technological advancements and their applications in the healthcare sector [1] - Investors are advised to be cautious of the volatility associated with consecutive limit-up stocks and to engage in rational investment practices [1]

Core Insights - The article highlights that Luyan Pharmaceutical (002788) has added the "Brain Engineering" concept due to its transaction records with the distributor of Borui Kang, which is the first company in China to complete clinical trials for minimally invasive brain-machine interfaces [1] Company Overview - Luyan Pharmaceutical's main business includes the distribution of pharmaceuticals, traditional Chinese medicine pieces, medical devices, and vaccines, as well as retail pharmacy chains [1] Financial Performance - For the first three quarters of 2025, Luyan Pharmaceutical reported a main revenue of 15.855 billion yuan, an increase of 2.87% year-on-year [1] - The net profit attributable to shareholders was 220 million yuan, a decrease of 14.64% year-on-year [1] - The net profit after deducting non-recurring items was also 220 million yuan, down 15.14% year-on-year [1] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 5.455 billion yuan, up 6.81% year-on-year [1] - The single-quarter net profit attributable to shareholders was 65.1366 million yuan, a decline of 2.74% year-on-year [1] - The single-quarter net profit after deducting non-recurring items was 66.6689 million yuan, down 7.93% year-on-year [1] - The company's debt ratio stands at 74.98%, with investment income reported at -10.8849 million yuan and financial expenses at 139 million yuan, while the gross profit margin is 6.96% [1]

Group 1 - The company emphasizes the importance of new technologies such as artificial intelligence and big data in the fields of healthcare and pharmaceuticals, and is conducting related research and exploration [2] - The company has not developed or applied the "Luyan-Alibaba Health AI Diagnosis Assistant" as of now [2] - Investors are advised to refer to the company's official announcements for accurate information [2]

Core Viewpoint - The company emphasizes the importance of new technologies such as artificial intelligence and big data in the medical and pharmaceutical fields, indicating ongoing research and exploration in these areas [1] Group 1 - The company has not yet developed or applied the "Luyan-Ali Health AI Diagnosis Assistant" [1]

Group 1 - Fujian local stocks experienced a significant afternoon rally, with companies such as Xiamen Port Authority, Fuzhijng Technology, and Snowman Group hitting the daily limit up [1] - Other stocks that followed the upward trend include Xingyun Co., Pingtan Development, Xiamen Airport, Dongbai Group, and Haixia Innovation [1] Group 2 - Notable stock performances include: - Hengkun New Materials (688727) with a rise of 62.06% and a one-year increase of 314.01% [2] - Snowman Group (002639) up by 21.96% with a one-year increase of 212.82% [2] - Xiamen Port Authority (000905) increased by 14.17% with a one-year rise of 124.92% [2] - Fuzhijng Technology (002222) surged by 63.98% with a one-year increase of 94.47% [2] - Luyan Pharmaceutical (002788) rose by 24.99% with a one-year increase of 213.55% [2] - Shengtun Mining (600711) increased by 17.31% with a one-year rise of 283.81% [2] - Huamao Technology (603306) up by 67.02% with a one-year increase of 107.81% [2] - Aerospace Development (000547) increased by 36.16% with a one-year rise of 383.42% [2] - Xingyun Co. (300648) rose by 55.87% with a one-year increase of 131.73% [2] - ST Green Kang (002868) increased by 39.03% with a one-year rise of 170.48% [2]

证券日报网讯1月6日，鹭燕医药（002788）在互动平台回答投资者提问时表示，经查询公司业务系统， 公司目前没有直接与博睿康医疗科技(上海)有限公司(简称"博睿康")交易的记录。但公司与博睿康的代 理商/经销商有采购博睿康相关产品的交易记录。 ...